RAPPORTEUR (EURACTIV) - Four in five countries now have a national cancer plan, but three in four governments have not costed theirs. From Mexico to Romania, the gap between strategy and results looks the same. Read more

EU PERSPECTIVES - As US drug pricing policy raises concerns over Europe's access to new medicines, lawmakers are urging member states to pool their bargaining power. The biotech industry, however, sees the pressure from Washington as a short-term shock and wants Europe to focus on its own competitiveness. Read more

EU PERSPECTIVES - A new medicine could reach the market the day it wins EU approval, yet stay out of reach for most patients. For Valentina Strammiello of the European Patients' Forum,that would only deepen inequality. And governments, she says, are waking up late. Read more

RAPPORTEUR (EURACTIV) - Belgium's prime minister links GSK's restructure plans to US investment pressure and Chinese subsidies for clinical trials. Read more